Home > Boards > US Listed > Biotechs > Vascular Biogenics Ltd. (VBLT)

VBLT 9 patients had complete response . Its

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
cjstocksup Member Profile
Member Level 
Followed By 3,602
Posts 233,478
Boards Moderated 0
Alias Born 07/30/07
160x600 placeholder
VET, TCOM, TTM and ZI among premarket gainers Seeking Alpha - 2/23/2021 8:18:53 AM
VBL Therapeutics gets green light for VB-111 study in ovarian cancer, shares up 16% Seeking Alpha - 2/22/2021 7:32:38 AM
VBL Therapeutics Announces Data Safety Monitoring Committee Provides Green Light to Advance the OVAL Phase 3 Registration Ena... GlobeNewswire Inc. - 2/22/2021 7:00:00 AM
VBL Therapeutics Treats First Patient in Phase 2 Randomized Controlled Study of VB-201 in COVID-19 Patients GlobeNewswire Inc. - 1/27/2021 7:00:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 1/15/2021 7:05:09 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 1/15/2021 7:03:58 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 1/11/2021 6:02:46 AM
Securities Registration (foreign Private Issuer) (f-3) Edgar (US Regulatory) - 12/30/2020 4:17:39 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/24/2020 4:51:30 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 11/16/2020 7:18:35 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/16/2020 7:03:18 AM
VBL Therapeutics to Report Third Quarter 2020 Financial Results on November 16 GlobeNewswire Inc. - 11/2/2020 7:00:10 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 10/29/2020 9:01:19 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 10/19/2020 4:10:50 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 10/13/2020 8:31:06 AM
VBL Therapeutics to Provide an Update on the OVAL Study Today at the H. C. Wainwright 22nd Annual Global Investment Conferenc... GlobeNewswire Inc. - 9/15/2020 8:00:10 AM
VBL Presents Human Proof-of-Concept Data That Show the Potential of its Novel anti-MOSPD2 Monoclonal Antibodies for Multiple ... GlobeNewswire Inc. - 9/11/2020 8:00:10 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 8/26/2020 5:21:36 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 8/13/2020 7:01:01 AM
VBL Therapeutics Announces Second Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire Inc. - 8/13/2020 7:00:10 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 8/12/2020 8:46:07 AM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 8/5/2020 4:33:05 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 8/3/2020 8:39:54 AM
VBL Therapeutics to Report Second Quarter 2020 Financial Results on August 13 GlobeNewswire Inc. - 8/3/2020 8:00:10 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/31/2020 6:29:30 AM
cjstocksup Member Level  Friday, 03/27/20 05:33:55 AM
Re: Oren1976 post# 1990
Post # of 2011 
VBLT 9 patients had complete response . Its 9 out of 32. 9 complete responder is large amount
Run shorts, and don't look back !!!
VBLT News - VBL Therapeutics Announces Positive Outcome of the Interim Analysis in the OVAL Phase 3 Ovarian Cancer Pivotal Study

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
© 2021 InvestorsHub.com, Inc.
Consent Preferences